Scott Myers has been a director since April 2020. Mr. Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology experience who has been President and Chief Executive Officer of AMAG since April 2020. Mr. Myers most recently served as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and Director of Cascadian Therapeutics Inc. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015. While at the helm of these companies, Mr. Myers drove transformation that maximized growth and delivered significant long-term value. Mr. Myers is currently an Independent Director for Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as an Independent Director for Harpoon Therapeutics, a clinical stage biotechnology company where he serves on the Audit Committee. Mr. Myers began his career in management consulting and then moved into the pharmaceutical industry through senior leadership roles at Johnson & Johnson, DOV Pharmaceuticals and UCB. Mr. Myers holds a Bachelor of Arts in Biology from Northwestern University in Evanston, Illinois, and a Master of Business Administration from The University of Chicago Graduate School of Business (Booth) in Chicago, Illinois.
As of November, 2020 AMAG Pharmaceuticals, Inc. is now a subsidiary of the Covis Pharma Group. For more information about Covis, please visit (covispharma.com)